Archive

« Older Entries

arGEN-X Announces Advancement of Therapeutic Antibody Alliance with Shire Thursday, December 11th, 2014
Shire to take one or more collaborative product candidates into preclinical development   Breda, The Netherlands / Ghent, Belgium, December 11, 2014 – arGEN-X N.V. (Euronext Brussels: ARGX), a clinical-stag [...]
Kiadis Pharma Presents Positive Data from a Pre-specified Interim Analysis of the Phase II Clinical Program with its Lead Product ATIR™ Tuesday, December 9th, 2014
~ Data confirms the potential of ATIR™ in partially matched hematopoietic stem cell transplants ~   Amsterdam, The Netherlands, December 9, 2014 – Kiadis Pharma B.V. (“Kiadis Pharma”), a clinica [...]
arGEN-X Reports Preclinical Data on ARGX-110 in Chronic Myelogenous Leukemia Model Tuesday, December 9th, 2014
Data to be presented at ASH demonstrate potential of ARGX-110 in reversing resistance to tyrosine kinase inhibitors   Breda, the Netherlands / Ghent, Belgium, December 8, 2014 – arGEN-X N.V. (Euronext Bruss [...]
Prosensa Wins Scrip 'Biotech Company of the Year' 2014 Award Wednesday, December 3rd, 2014
Leiden, The Netherlands, Dec. 8, 2014 (GLOBE NEWSWIRE) -- Prosensa Holding N.V. (NASDAQ: RNA), the biopharmaceutical company focusing on RNA-modulating therapeutics for rare diseases with a high unmet medical need [...]
LSP invests in Xeltis, a leading regenerative medicine company Tuesday, December 2nd, 2014
Amsterdam, the Netherlands, December 2, 2014. LSP (Life Sciences Partners), a leading European investor in health care, announces its investment in Xeltis, a private Swiss/Dutch regenerative medicine company developin [...]
LSP's portfolio company EyeSense enters strategic partnership with Lee’s Pharmaceutical Holdings Thursday, November 27th, 2014
Through the attached press release we are happy to announce the strategic partnership between our portfolio company EyeSense and Lee’s Pharmaceutical  (Lee’s PHARM” - Hong Kong Stock Exchange; Stock Code 950). [...]
Leve de wetenschap Thursday, November 27th, 2014
De Nederlandse wetenschap is top. Durfinvesteerder LSP schrijft het nog eens op zijn website: de verkoop van biotechbedrijf Prosensa ‘is weer een illustratie van het potentieel van de Nederlandse wetenschap’.   [...]
LSP invests in Curetis, a leading molecular diagnostics company Monday, November 24th, 2014
Amsterdam, the Netherlands, 24 November 2014. LSP (Life Sciences Partners), a leading European investor in health care, announces its investment in Curetis, a private German molecular diagnostic company developing and [...]
LSP's portfolio company Prosensa receives tender offer from BioMarin Monday, November 24th, 2014
Through the attached press release we are very happy to announce the agreement between BioMarin and Prosensa  on the intended public offer for 100% of Prosensa’s outstanding stock. The total deal size is around $ 8 [...]
STALLERGENES AND ACTOGENIX TO DEVELOP AN INNOVATIVE NEW CLASS OF ORAL ALLERGY TREATMENTS Friday, November 21st, 2014
STALLERGENES exercised option to pursue the exclusive development of application of ActoGeniX’s technology for targeted delivery of allergen-based treatments Antony, France and Ghent, Belgium – 20 Novem [...]

« Older Entries

2018
2017
2016
2015
2014
2013
2012
back to archive overview

Archive

« Older Entries

arGEN-X Announces Advancement of Therapeutic Antibody Alliance with Shire Thursday, December 11th, 2014
Shire to take one or more collaborative product candidates into preclinical development   Breda, The Netherlands / Ghent, Belgium, December 11, 2014 – arGEN-X N.V. (Euronext Brussels: ARGX), a clinical-stag [...]
Kiadis Pharma Presents Positive Data from a Pre-specified Interim Analysis of the Phase II Clinical Program with its Lead Product ATIR™ Tuesday, December 9th, 2014
~ Data confirms the potential of ATIR™ in partially matched hematopoietic stem cell transplants ~   Amsterdam, The Netherlands, December 9, 2014 – Kiadis Pharma B.V. (“Kiadis Pharma”), a clinica [...]
arGEN-X Reports Preclinical Data on ARGX-110 in Chronic Myelogenous Leukemia Model Tuesday, December 9th, 2014
Data to be presented at ASH demonstrate potential of ARGX-110 in reversing resistance to tyrosine kinase inhibitors   Breda, the Netherlands / Ghent, Belgium, December 8, 2014 – arGEN-X N.V. (Euronext Bruss [...]
Prosensa Wins Scrip 'Biotech Company of the Year' 2014 Award Wednesday, December 3rd, 2014
Leiden, The Netherlands, Dec. 8, 2014 (GLOBE NEWSWIRE) -- Prosensa Holding N.V. (NASDAQ: RNA), the biopharmaceutical company focusing on RNA-modulating therapeutics for rare diseases with a high unmet medical need [...]
LSP invests in Xeltis, a leading regenerative medicine company Tuesday, December 2nd, 2014
Amsterdam, the Netherlands, December 2, 2014. LSP (Life Sciences Partners), a leading European investor in health care, announces its investment in Xeltis, a private Swiss/Dutch regenerative medicine company developin [...]
LSP's portfolio company EyeSense enters strategic partnership with Lee’s Pharmaceutical Holdings Thursday, November 27th, 2014
Through the attached press release we are happy to announce the strategic partnership between our portfolio company EyeSense and Lee’s Pharmaceutical  (Lee’s PHARM” - Hong Kong Stock Exchange; Stock Code 950). [...]
Leve de wetenschap Thursday, November 27th, 2014
De Nederlandse wetenschap is top. Durfinvesteerder LSP schrijft het nog eens op zijn website: de verkoop van biotechbedrijf Prosensa ‘is weer een illustratie van het potentieel van de Nederlandse wetenschap’.   [...]
LSP invests in Curetis, a leading molecular diagnostics company Monday, November 24th, 2014
Amsterdam, the Netherlands, 24 November 2014. LSP (Life Sciences Partners), a leading European investor in health care, announces its investment in Curetis, a private German molecular diagnostic company developing and [...]
LSP's portfolio company Prosensa receives tender offer from BioMarin Monday, November 24th, 2014
Through the attached press release we are very happy to announce the agreement between BioMarin and Prosensa  on the intended public offer for 100% of Prosensa’s outstanding stock. The total deal size is around $ 8 [...]
STALLERGENES AND ACTOGENIX TO DEVELOP AN INNOVATIVE NEW CLASS OF ORAL ALLERGY TREATMENTS Friday, November 21st, 2014
STALLERGENES exercised option to pursue the exclusive development of application of ActoGeniX’s technology for targeted delivery of allergen-based treatments Antony, France and Ghent, Belgium – 20 Novem [...]

« Older Entries

2018
2017
2016
2015
2014
2013
2012
back to archive overview